+关注
CHUMOI
暂无个人介绍
IP属地：未知
435
关注
15
粉丝
0
主题
0
勋章
主贴
热门
CHUMOI
2021-11-06
Details
Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?
CHUMOI
2021-09-28
Ok
抱歉，原内容已删除
CHUMOI
2021-12-03
[What]
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3585564713983052,"uuid":"3585564713983052","gmtCreate":1622470689847,"gmtModify":1622470689847,"name":"CHUMOI","pinyin":"chumoi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":15,"headSize":435,"tweetSize":66,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":601558275,"gmtCreate":1638543702759,"gmtModify":1638543702862,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[What] ","listText":"[What] ","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601558275","repostId":"1121551693","repostType":4,"repost":{"id":"1121551693","pubTimestamp":1638540582,"share":"https://www.laohu8.com/m/news/1121551693?lang=&edition=full","pubTime":"2021-12-03 22:09","market":"us","language":"en","title":"Netflix Loses Appeal in Lawsuit Over Poaching of Fox Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=1121551693","media":"Bloomber","summary":"Trial court blocked Netflix from poaching Fox employees\nExecutives weren’t coerced into signing exte","content":"<ul>\n <li>Trial court blocked Netflix from poaching Fox employees</li>\n <li>Executives weren’t coerced into signing extensions</li>\n</ul>\n<p>Netflix Inc.lost its challenge to an order that the streaming giant stop poaching fixed-term employees fromTwentieth Century Fox, after a California appellate court upheld the injunction on Thursday.</p>\n<p>Fox sued the streaming service in 2016, alleging Netflix enticed certain Fox executives to leave the company, breaking fixed-term contracts.</p>\n<p>A state trial court in Los Angeles granted an injunction blocking Netflix from soliciting Fox employees on fixed-term employment agreements or inducing them to breach their agreements.</p>\n<p>The California Court of Appeal, Second District, upheld the injunction, rejecting Netflix’s argument that Fox’s fixed-term contracts were unconscionable and against public policy.</p>\n<p>The California Supreme Court has observed that there are public policy benefits to fixed-term contracts, Justice Dorothy C. Kim wrote in the unpublished opinion. And other provisions, including a confidentiality provision and a nonsolicitation provision, do not violate public policy, Kim said.</p>\n<p>Fox’s agreements provided “stability and predictability” for employees, Kim said. She also rejected Netflix’s argument that Fox pressured employees into extending their contracts, thereby holding them under contract longer than the legally allowed limit under California law.</p>\n<p>The poached employees in question were “sophisticated business executives who negotiated their fixed-term employment agreements with Fox at arm’s length,” Kim wrote. Nothing in the record indicated a restraint on mobility or any other public policy violation, she said.</p>\n<p>Justices Carl H. Moor and Brian M. Hoffstadt joined the opinion.</p>\n<p>Orrick, Herrington & Sutcliffe represents Netflix. O’Melveny & Myers represents Fox.</p>\n<p>The case is Twentieth Century Fox Film Corp. v. Netflix, Cal. Ct. App., 2d Dist., No. B304022, unpublished 12/2/21.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Loses Appeal in Lawsuit Over Poaching of Fox Executives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Loses Appeal in Lawsuit Over Poaching of Fox Executives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 22:09 GMT+8 <a href=https://news.bloomberglaw.com/us-law-week/netflix-loses-appeal-in-lawsuit-over-poaching-of-fox-executives><strong>Bloomber</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trial court blocked Netflix from poaching Fox employees\nExecutives weren’t coerced into signing extensions\n\nNetflix Inc.lost its challenge to an order that the streaming giant stop poaching fixed-term...</p>\n\n<a href=\"https://news.bloomberglaw.com/us-law-week/netflix-loses-appeal-in-lawsuit-over-poaching-of-fox-executives\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://news.bloomberglaw.com/us-law-week/netflix-loses-appeal-in-lawsuit-over-poaching-of-fox-executives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121551693","content_text":"Trial court blocked Netflix from poaching Fox employees\nExecutives weren’t coerced into signing extensions\n\nNetflix Inc.lost its challenge to an order that the streaming giant stop poaching fixed-term employees fromTwentieth Century Fox, after a California appellate court upheld the injunction on Thursday.\nFox sued the streaming service in 2016, alleging Netflix enticed certain Fox executives to leave the company, breaking fixed-term contracts.\nA state trial court in Los Angeles granted an injunction blocking Netflix from soliciting Fox employees on fixed-term employment agreements or inducing them to breach their agreements.\nThe California Court of Appeal, Second District, upheld the injunction, rejecting Netflix’s argument that Fox’s fixed-term contracts were unconscionable and against public policy.\nThe California Supreme Court has observed that there are public policy benefits to fixed-term contracts, Justice Dorothy C. Kim wrote in the unpublished opinion. And other provisions, including a confidentiality provision and a nonsolicitation provision, do not violate public policy, Kim said.\nFox’s agreements provided “stability and predictability” for employees, Kim said. She also rejected Netflix’s argument that Fox pressured employees into extending their contracts, thereby holding them under contract longer than the legally allowed limit under California law.\nThe poached employees in question were “sophisticated business executives who negotiated their fixed-term employment agreements with Fox at arm’s length,” Kim wrote. Nothing in the record indicated a restraint on mobility or any other public policy violation, she said.\nJustices Carl H. Moor and Brian M. Hoffstadt joined the opinion.\nOrrick, Herrington & Sutcliffe represents Netflix. O’Melveny & Myers represents Fox.\nThe case is Twentieth Century Fox Film Corp. v. Netflix, Cal. Ct. App., 2d Dist., No. B304022, unpublished 12/2/21.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842406485,"gmtCreate":1636211106607,"gmtModify":1636211106895,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Details","listText":"Details","text":"Details","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/842406485","repostId":"2181742241","repostType":4,"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862197036,"gmtCreate":1632841862665,"gmtModify":1632841862759,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862197036","repostId":"2170672462","repostType":4,"repost":{"id":"2170672462","pubTimestamp":1632835246,"share":"https://www.laohu8.com/m/news/2170672462?lang=&edition=full","pubTime":"2021-09-28 21:20","market":"us","language":"en","title":"Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2170672462","media":"Motley Fool","summary":"Bargains can still be found, even with the broader market near an all-time high.","content":"<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark <b>S&P 500</b> took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.</p>\n<p>But just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8cf8fd6cbc9120f885acecdfb00d5835\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Novavax</h2>\n<p>While I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock <b>Novavax</b> (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.</p>\n<p>The company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from <b>AstraZeneca</b>'s and <b>Johnson & Johnson</b>'s COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.</p>\n<p>Also working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.</p>\n<p>Novavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d9e4dd60375f8f383f0c222a7633a4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis</h2>\n<p>Biotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer <b>Exelixis</b> (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.</p>\n<p>The superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.</p>\n<p>The only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.</p>\n<p>While this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e5596b9cd58d43ee65824bd7892b9c5e\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Broadcom</h2>\n<p>Stepping outside the healthcare arena for the moment, semiconductor solutions provider <b>Broadcom</b> (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.</p>\n<p>First, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.</p>\n<p>But it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.</p>\n<p>The icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2fc0013108c05865a77a8fa2e9b54b23\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Vertex Pharmaceuticals</h2>\n<p>Similar to Exelixis, specialty biotech stock <b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.</p>\n<p>What allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.</p>\n<p>Keeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.</p>\n<p>And don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39a1727edeb0317fbc6386d8981fd8e0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health</h2>\n<p>Lastly, buying shares of telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.</p>\n<p>When the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.</p>\n<p>Some skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.</p>\n<p>Teladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 21:20 GMT+8 <a href=https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","AVGO":"博通","TDOC":"Teladoc Health Inc.","NVAX":"诺瓦瓦克斯医药","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170672462","content_text":"If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.\nBut just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.\nImage source: Getty Images.\nNovavax\nWhile I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock Novavax (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.\nThe company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from AstraZeneca's and Johnson & Johnson's COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.\nAlso working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.\nNovavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.\nImage source: Getty Images.\nExelixis\nBiotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer Exelixis (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.\nThe superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.\nThe only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.\nWhile this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.\nImage source: Getty Images.\nBroadcom\nStepping outside the healthcare arena for the moment, semiconductor solutions provider Broadcom (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.\nFirst, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.\nBut it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.\nThe icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.\nImage source: Getty Images.\nVertex Pharmaceuticals\nSimilar to Exelixis, specialty biotech stock Vertex Pharmaceuticals (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.\nWhat allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.\nKeeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.\nAnd don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.\nImage source: Getty Images.\nTeladoc Health\nLastly, buying shares of telemedicine kingpin Teladoc Health (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.\nWhen the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.\nSome skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.\nTeladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.","news_type":1},"isVote":1,"tweetType":1,"viewCount":397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":842406485,"gmtCreate":1636211106607,"gmtModify":1636211106895,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Details","listText":"Details","text":"Details","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/842406485","repostId":"2181742241","repostType":4,"repost":{"id":"2181742241","pubTimestamp":1636200000,"share":"https://www.laohu8.com/m/news/2181742241?lang=&edition=full","pubTime":"2021-11-06 20:00","market":"us","language":"en","title":"Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?","url":"https://stock-news.laohu8.com/highlight/detail?id=2181742241","media":"Motley Fool","summary":"Probably, but there will be room for other players in the COVID-19 vaccine market, too.","content":"<p><b>Pfizer</b> (NYSE:PFE) and <b>Moderna</b> (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this <i>Motley Fool Live</i> video <b>recorded on Oct. 27</b>, Fool contributors Keith Speights and Brian Orelli address this question, as well as the potential for other companies to succeed.</p>\n<p><b>Keith Speights:</b> Now, here's <a href=\"https://laohu8.com/S/AONE.U\">one</a> that I think that we both can talk about here. Joe asked, \"Where do you see the COVID market going if the pandemic becomes an epidemic?\" He also says, \"Will Moderna and Pfizer continue to lead? Where will <b>CureVac</b> (NASDAQ:CVAC) and <b>Novavax</b> (NASDAQ:NVAX) fit in in such a scenario?\" That's a good question.</p>\n<p><b>Brian Orelli:</b> I wonder whether he means endemic which means it's around all the time. Pandemic would be it comes and then goes. Endemic means it's like the flu. It's around every year, you are never going to actually get rid of it.</p>\n<p>I think Moderna and Pfizer are definitely going to continue to lead because they have such a head start, not just in the ability, doctors having experience with it, but also their ability to manufacture quite a bit of it. I think they will definitely continue to lead.</p>\n<p>Is there room for Novavax and CureVac? I think there probably is.</p>\n<p>I think that it's really going to depend on whether we need more boosters. We don't really know what our memory B cells are going to do and what the virus is going to do. That's basically, the virus mutates enough, then our memory B cells can't take care of the virus then it will be a problem. If the virus doesn't mutate enough and then we're all vaccinated and we have fairly good memory B cells, well then we get infected with the coronavirus and SARS-CoV-2 and our bodies just take care of it and maybe we get sniffles or something.</p>\n<p>But it's not a major issue. We don't worry about the cold. I don't think we'd have much problems. I don't think there was going to be that big of a market for boosters if people aren't dying from COVID-19.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 20:00 GMT+8 <a href=https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this Motley Fool Live video recorded on Oct....</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181742241","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this Motley Fool Live video recorded on Oct. 27, Fool contributors Keith Speights and Brian Orelli address this question, as well as the potential for other companies to succeed.\nKeith Speights: Now, here's one that I think that we both can talk about here. Joe asked, \"Where do you see the COVID market going if the pandemic becomes an epidemic?\" He also says, \"Will Moderna and Pfizer continue to lead? Where will CureVac (NASDAQ:CVAC) and Novavax (NASDAQ:NVAX) fit in in such a scenario?\" That's a good question.\nBrian Orelli: I wonder whether he means endemic which means it's around all the time. Pandemic would be it comes and then goes. Endemic means it's like the flu. It's around every year, you are never going to actually get rid of it.\nI think Moderna and Pfizer are definitely going to continue to lead because they have such a head start, not just in the ability, doctors having experience with it, but also their ability to manufacture quite a bit of it. I think they will definitely continue to lead.\nIs there room for Novavax and CureVac? I think there probably is.\nI think that it's really going to depend on whether we need more boosters. We don't really know what our memory B cells are going to do and what the virus is going to do. That's basically, the virus mutates enough, then our memory B cells can't take care of the virus then it will be a problem. If the virus doesn't mutate enough and then we're all vaccinated and we have fairly good memory B cells, well then we get infected with the coronavirus and SARS-CoV-2 and our bodies just take care of it and maybe we get sniffles or something.\nBut it's not a major issue. We don't worry about the cold. I don't think we'd have much problems. I don't think there was going to be that big of a market for boosters if people aren't dying from COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862197036,"gmtCreate":1632841862665,"gmtModify":1632841862759,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862197036","repostId":"2170672462","repostType":4,"isVote":1,"tweetType":1,"viewCount":397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601558275,"gmtCreate":1638543702759,"gmtModify":1638543702862,"author":{"id":"3585564713983052","authorId":"3585564713983052","name":"CHUMOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[What] ","listText":"[What] ","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601558275","repostId":"1121551693","repostType":4,"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
